AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03906695
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral decitabine 10mg + cedazuridine
Trial: NCT02078973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Unikalk pr day for 1 day
Trial: NCT02548728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
Trial: NCT01476345
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT02328469
Drug: symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
Trial: NCT00923728
Drug: AVN944
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03945760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02328469
Drug: Ceftriaxone or Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
Trial: NCT00568776
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELND005 matched placebo capsules for oral administration, bid for 78 weeks
Trial: NCT00568776
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
Trial: NCT00568776
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
Trial: NCT00568776
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
Trial: NCT00425516
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00277394
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
Trial: NCT01964196
Drug: ASP1517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01964196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02492737
Drug: AG881
RxNorm normalized name: Agenebrutinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Trial: NCT04071236
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03710876
Drug: Celecoxib Oral Product
RxNorm normalized name: celecoxib Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily
Trial: NCT01413100
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02128100
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
Trial: NCT04259801
Drug: NNC0480-0389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
Trial: NCT04259801
Drug: Placebo (NNC0480-0389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
Trial: NCT04259801
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Trial: NCT03761797
Drug: TRADIANCE® Combination Tablets AP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination
Trial: NCT03761797
Drug: TRADIANCE® Combination Tablets BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination
Trial: NCT01096706
Drug: NO clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Trial: NCT02203552
Drug: minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg bid given by mouth for 9 weeks
Trial: NCT04059770
Drug: single dose of L-AmB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (i) single IV dose of 10 mg/kg of L-AmB on day 1;
Trial: NCT04059770
Drug: 2 doses of L-AmB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
Trial: NCT04059770
Drug: 2 weeks of L-AmB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
Trial: NCT01096706
Drug: Combined
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms.
Trial: NCT00589693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
Trial: NCT01098383
Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements
RxNorm normalized name: Choline esterase
DrugBank: Butyrylcholinesterase (DB06352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose.
Trial: NCT03872011
Drug: Vitamin C,thiamine,hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU.
Trial: NCT03872011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Trial: NCT00645788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg matching placebo powder formulation twice a day for 28 days
Trial: NCT02852694
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
Trial: NCT00645788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
Trial: NCT00400153
Drug: Atrovent Respimat (20 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00400153
Drug: COMBIVENT MDI (36/206 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01423604
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
Trial: NCT01423604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching ruxolitinib
Trial: NCT02241200
Drug: DA3880
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02076230
Drug: [14C] TH-302 (Label 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Trial: NCT02076230
Drug: [14C] TH-302 (Label 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Trial: NCT02955810
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02379338
Drug: [18F]Fluortriopride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a \[18F\]Fluortriopride PET/CT scan
Trial: NCT04275388
Drug: Xiyanping injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
Trial: NCT03467386
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01518985
Drug: Bendavia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
Trial: NCT01518985
Drug: Sterile saline (0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
Trial: NCT03924986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match tislelizumab (administered intravenously Q3W)
Trial: NCT01787188
Drug: Meloxicam Test Capsules
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01428661
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00445068
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03740178
Drug: MK-4334
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Trial: NCT03740178
Drug: Placebo to MK-4334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Trial: NCT03740178
Drug: Donepepzil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
Trial: NCT01938742
Drug: MF59
RxNorm normalized name: vaccine adjuvant emulsion MF59C.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
Trial: NCT00597727
Drug: Placebo SLIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid glycerin without peanut which are dosed under the tongue.
Trial: NCT00200590
Drug: acetaminophen and morphine
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00200590
Drug: acetaminophen and reduced dosage of prostaglandin
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04200781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules has the same appearence, weight, shape and color as the experimental drug.
Trial: NCT00246441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
Trial: NCT00003119
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003119
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02017535
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
Trial: NCT04340427
Drug: TQB3455
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
Trial: NCT01393626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets twice daily
Trial: NCT00963599
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken once daily at bed time for 2 weeks
Trial: NCT04976088
Drug: Diclofenac Sodium 140 mg medicated plaster
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
Trial: NCT04976088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Placebo plaster, topical application once a day.
Trial: NCT00390793
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00390793
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01958593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
Trial: NCT00390793
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT00219544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01958112
Drug: GSK2141795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of GSK2141795 is 50 mg orally once per day
Trial: NCT00056498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 16 weeks
Trial: NCT03231982
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
Trial: NCT03231982
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
Trial: NCT00814801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
Trial: NCT04432220
Drug: Anticoagulation group(Apixaban group)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Trial: NCT03496207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01370434
Drug: PAD combination
RxNorm normalized name: PADS,COMBINATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11
Trial: NCT01766310
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
Trial: NCT01766310
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar tablet manufactured to mimic folic acid tablet
Trial: NCT03224117
Drug: DWJ211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inject the Drug into submental fat via subcutaneous
Trial: NCT03224117
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inject the Drug into submental fat via subcutaneous
Trial: NCT02996617
Drug: rhG-CSF regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Trial: NCT02996617
Drug: Pegylated rhG-CSF regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Trial: NCT00719758
Drug: TRK-100STP (BERASUS LA)
RxNorm normalized name: PRUNUS CERASUS FLOWER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03310320
Drug: AZD0284 oral solution 2.5 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
Trial: NCT03310320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for AZD0284 oral solution, twice daily for 4 weeks
Trial: NCT01256398
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01256398
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO